Effects of different promoters on the virulence and immunogenicity of a HIV-1 Env-expressing recombinant vaccinia vaccine

Vaccine

Volumn 32, Issue 7, 2014, Pages 839-845

  Isshiki, Mao ^a   Zhang, Xianfeng ^a   Sato, Hirotaka ^a,c   Ohashi, Takashi ^a   Inoue, Makoto ^b   Shida, Hisatoshi ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

^b DNAVEC Corporation   (Japan)

^c RIKEN   (Japan)

Author keywords

HIV 1 Env; Immunogenicity; LC16m8 ; Promoter p7.5; Promoter pSFJ1 10; Safety

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; GAMMA INTERFERON; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOGLOBULIN G; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; NEUTRALIZING ANTIBODY; RECOMBINANT VACCINE; SMALLPOX VACCINE; VACCINIA VACCINE; VIRUS ENVELOPE PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN SPECIFICITY; ARTICLE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; ENVELOPE GENE; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMORAL IMMUNITY; IMMUNOGENICITY; IN VITRO STUDY; LYMPHOCYTE SUBPOPULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; SPLEEN CELL; VACCINATION; VIROGENESIS; VIRUS EXPRESSION; VIRUS STRAIN; VIRUS VIRULENCE; WESTERN BLOTTING;

HIV-1 ENV; IMMUNOGENICITY; LC16M8Δ; PROMOTER P7.5; PROMOTER PSFJ1-10; SAFETY;

AIDS VACCINES; ANIMALS; CELL LINE; FEMALE; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP160; HIV-1; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; MICE, INBRED C57BL; PROMOTER REGIONS, GENETIC; RABBITS; T-LYMPHOCYTES, CYTOTOXIC; VACCINES, SYNTHETIC; VACCINIA VIRUS;

EID: 84892867041     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.12.022     Document Type: Article

References (17)

1. Rerks-Ngarm S., Pitisuttithum P., Nitayaphan S., Kaewkungwal J., Chiu J., Paris R., et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009, 361:2209-2220.
2. Zhang X., Sobue T., Isshiki M., Makino S., Inoue M., Kato K., et al. Elicitation of both anti HIV-1 Env humoral and cellular immunities by replicating vaccinia prime Sendai virus boost regimen and boosting by CD40Lm. PLoS ONE 2012, 7:e51633.
3. Kenner J., Cameron F., Empig C., Jobes D.V., Gurwith M. LC16m8: an attenuated smallpox vaccine. Vaccine 2006, 24:7009-7022.
4. Kidokoro M., Tashiro M., Shida H. Genetically stable and fully effective smallpox vaccine strain constructed from highly attenuated vaccinia LC16m8. Proc Natl Acad Sci U S A 2005, 102:4152-4157.
5. Gomez C.E., Najera J.L., Jimenez E.P., Jimenez V., Wagner R., Graf M., et al. Head-to head comparison on the immunogenicity of two HIV/AIDS vaccine candidates based on the attenuated poxvirus strains MVA and NYVAC co-expressing in a single locus the HIV-1BX08 gp120 and HIV-1(IIIB) Gag-Pol-Nef proteins of clade B. Vaccine 2007, 25:2863-2885.
6. Zhou J.A., McIndoe A., Davies H., Sun X.Y., Crawford L. The induction of cytotoxic T-lymphocyte precursor cells by recombinant vaccinia virus expressing human papillomavirus type 16 L1. Virology 1991, 181:203-210.
7. Townsend A., Bastin J., Gould K., Brownlee G., Andrew M., Coupar B., et al. Defective presentation to class I-restricted cytotoxic T lymphocytes in vaccinia-infected cells is overcome by enhanced degradation of antigen. J Exp Med 1988, 168:1211-1224.
8. Jin N.Y., Funahashi S., Shida H. Constructions of vaccinia virus A-type inclusion body protein, tandemly repeated mutant 7.5kDa protein, and hemagglutinin gene promoters support high levels of expression. Arch Virol 1994, 138:315-330.
9. Kidokoro M., Aoki A., Horiuchi K., Shida H. Large-scale preparation of biologically active measles virus haemagglutinin expressed by attenuated vaccinia virus vectors. Microbes Infect 2002, 4:1035-1044.
10. Platt E.J., Wehrly K., Kuhmann S.E., Chesebro B., Kabat D. Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1. J Virol 1998, 72:2855-2864.
11. Wei X., Decker J.M., Liu H., Zhang Z., Arani R.B., Kilby J.M., et al. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother 2002, 46:1896-1905.
12. Itamura S., Morikawa Y., Shida H., Nerome K., Oya A. Biological and immunological characterization of influenza virus haemagglutinin expressed from the haemagglutinin locus of vaccinia virus. J Gen Virol 1990, 71(Pt 6):1293-1301.
13. Shida H., Matsumoto S. Analysis of the hemagglutinin glycoprotein from mutants of vaccinia virus that accumulates on the nuclear envelope. Cell 1983, 33:423-434.
14. Shida H., Tochikura T., Sato T., Konno T., Hirayoshi K., Seki M., et al. Effect of the recombinant vaccinia viruses that express HTLV-I envelope gene on HTLV-I infection. EMBO J 1987, 6:3379-3384.
15. Li M., Gao F., Mascola J.R., Stamatatos L., Polonis V.R., Koutsoukos M., et al. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol 2005, 79:10108-10125.
16. Montefiori D.C. Evaluating neutralizing antibodies against HIV, SIV, and SHIV in luciferase reporter gene assays. Curr Protoc Immunol 2005, 11. [Chapter 12: Unit 12].
17. Sato H., Jing C., Isshiki M., Matsuo K., Kidokoro M., Takamura S., et al. Immunogenicity and safety of the vaccinia virus LC16m8Delta vector expressing SIV Gag under a strong or moderate promoter in a recombinant BCG prime-recombinant vaccinia virus boost protocol. Vaccine 2013, 31:3549-3557.